Ser424

Site Information
DHDNDKEsDVEI___ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 455624
Available spectra: 4 CST

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 32 ) , immunoprecipitation ( 1 , 4 , 6 ) , mass spectrometry ( 2 , 5 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ) , modification-specific antibody ( 6 ) , mutation of modification site ( 32 ) , phospho-antibody ( 4 , 6 , 32 ) , phosphoamino acid analysis ( 32 ) , phosphopeptide mapping ( 32 ) , western blotting ( 1 , 4 , 6 , 32 )
Disease tissue studied:	breast cancer ( 4 , 5 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , cervical cancer ( 4 ) , cervical adenocarcinoma ( 4 ) , non-small cell lung cancer ( 19 , 20 , 22 ) , non-small cell lung adenocarcinoma ( 20 ) , lymphoma ( 8 ) , Burkitt's lymphoma ( 8 ) , follicular lymphoma ( 8 ) , mantle cell lymphoma ( 8 ) , neuroblastoma ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 1 , 32 ) , A498 (renal) ( 26 ) , A549 (pulmonary) ( 11 ) , BJAB (B lymphocyte) ( 8 ) , breast ( 2 ) , BT-474 (breast cell) ( 5 ) , Cal-12T (pulmonary) ( 17 ) , Calu-3 (pulmonary) ( 13 ) , DMS153 (pulmonary) ( 16 ) , DMS53 (pulmonary) ( 10 ) , DMS79 (pulmonary) ( 9 ) , FL-318 (B lymphocyte) ( 8 ) , HCC15 (pulmonary) ( 14 ) , HCC44 (pulmonary) ( 17 ) , HCC78 (pulmonary) ( 15 ) , HCC827 (pulmonary) ( 13 ) , HEK293T (epithelial) ( 6 ) , HeLa (cervical) ( 21 , 25 , 29 , 31 , 32 ) , HeLa S3 (cervical) ( 4 ) , JEKO-1 (B lymphocyte) ( 8 ) , Jurkat (T lymphocyte) ( 24 , 27 , 28 , 30 ) , K562 (erythroid) ( 21 ) , LOU-NH91 (squamous) ( 14 ) , lung ( 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ) , MCF-7 (breast cell) ( 4 , 5 ) , NCEB-1 (B lymphocyte) ( 8 ) , NCI-H128 (pulmonary) ( 9 ) , NCI-H1299 (pulmonary) ( 12 ) , NCI-H1355 (pulmonary) ( 11 ) , NCI-H1417 (pulmonary) ( 9 ) , NCI-H1437 (pulmonary) ( 16 , 17 ) , NCI-H1650 (pulmonary) ( 13 ) , NCI-H1666 (pulmonary) ( 17 ) , NCI-H1703 (squamous) ( 14 ) , NCI-H1734 (pulmonary) ( 12 ) , NCI-H1781 (pulmonary) ( 15 ) , NCI-H1792 (pulmonary) ( 11 ) , NCI-H1944 (pulmonary) ( 12 ) , NCI-H1975 (pulmonary) ( 13 ) , NCI-H2073 (pulmonary) ( 14 , 16 ) , NCI-H209 (pulmonary) ( 9 , 16 ) , NCI-H2106 (pulmonary) ( 13 ) , NCI-H2228 (pulmonary) ( 15 , 20 ) , NCI-H23 (pulmonary) ( 11 ) , NCI-H2342 (pulmonary) ( 14 ) , NCI-H2405 (pulmonary) ( 17 ) , NCI-H3122 (pulmonary) ( 15 , 19 ) , NCI-H3255 (pulmonary) ( 22 ) , NCI-H358 (pulmonary) ( 12 ) , NCI-H441 (pulmonary) ( 11 ) , NCI-H446 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 12 ) , NCI-H524 (pulmonary) ( 9 ) , NCI-H526 (pulmonary) ( 10 ) , NCI-H661 (pulmonary) ( 15 ) , NCI-H69 (pulmonary) ( 10 ) , NCI-H82 (pulmonary) ( 10 ) , NCI-H838 (pulmonary) ( 16 ) , OCI-ly1 (B lymphocyte) ( 8 ) , Raji (B lymphocyte) ( 8 ) , RAMOS (B lymphocyte) ( 8 ) , SH-SY5Y (neural crest) ( 1 ) , SU-DHL-4 (B lymphocyte) ( 8 )

Upstream Regulation
Putative in vivo kinases:	CK2A1 (human) ( 4 ) , LRRK2 (human) ( 1 )
Kinases, in vitro:	CK2A1 (human) ( 4 , 32 )
Putative upstream phosphatases:	PPP4C (human) ( 32 )
Treatments:	EGF ( 6 ) , insulin ( 6 )

Downstream Regulation
Effects of modification on HDAC3:	acetylation ( 1 ) , enzymatic activity, induced ( 1 , 4 , 32 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:	cell cycle regulation ( 4 )
Induce interaction with:	KPNA2 (human) ( 1 ) , PKG1 (human) ( 6 )

References
1	Han KA, et al. (2017) Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation. Hum Mol Genet 26, 1-18 27798112 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Patil H, et al. (2016) Mitotic Activation of a Novel Histone Deacetylase 3-Linker Histone H1.3 Protein Complex by Protein Kinase CK2. J Biol Chem 291, 3158-72 26663086 Curated Info
5	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
6	Wang S, et al. (2015) Insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1. PLoS Biol 13, e1002243 26356530 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
18	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
19	Rikova K (2013) CST Curation Set: 18857; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](PSD) Curated Info
20	Rikova K (2013) CST Curation Set: 18856; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](PSD) Curated Info
21	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
22	Rikova K (2012) CST Curation Set: 15873; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](PSD) Curated Info
23	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
24	Guo A (2011) CST Curation Set: 12456; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V) Curated Info
25	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
26	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
27	Guo A (2010) CST Curation Set: 9182; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
28	Guo A (2010) CST Curation Set: 9181; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
29	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
30	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
31	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
32	Zhang X, et al. (2005) Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 19, 827-39 15805470 Curated Info